1,901
Views
2
CrossRef citations to date
0
Altmetric
ALS Untangled

ALSUntangled #67: rituximab

, , , , ORCID Icon, , , , , , , , , , , , , , ORCID Icon, , , , , ORCID Icon & show all
Pages 544-547 | Received 22 Jul 2022, Accepted 04 Sep 2022, Published online: 15 Sep 2022
 

Abstract

ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.

Declaration of interest

No potential conflict of interest was reported by the author(s).

Additional information

Funding

ALSUntangled is sponsored by ALS Association [Grant 23-SI-622].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.